319 related articles for article (PubMed ID: 20647037)
21. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy.
Nadin SB; Vargas-Roig LM; Drago G; Ibarra J; Ciocca DR
Cancer Lett; 2006 Jul; 239(1):84-97. PubMed ID: 16143448
[TBL] [Abstract][Full Text] [Related]
22. The role of microRNA in cisplatin resistance or sensitivity.
Wang S; Li MY; Liu Y; Vlantis AC; Chan JY; Xue L; Hu BG; Yang S; Chen MX; Zhou S; Guo W; Zeng X; Qiu S; van Hasselt CA; Tong MC; Chen GG
Expert Opin Ther Targets; 2020 Sep; 24(9):885-897. PubMed ID: 32559147
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.
Shen DW; Pouliot LM; Hall MD; Gottesman MM
Pharmacol Rev; 2012 Jul; 64(3):706-21. PubMed ID: 22659329
[TBL] [Abstract][Full Text] [Related]
25. [Advances of DNA damage repair and Cisplatin resistance mechanisms in lung cancer].
Tang C; Yang H; Zhou X
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):960-4. PubMed ID: 22152698
[TBL] [Abstract][Full Text] [Related]
26. [Advance in studies on molecular mechanisms of cisplatin resistance and intervention with traditional Chinese medicines].
Liu L; Bian K
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3216-20. PubMed ID: 25522600
[TBL] [Abstract][Full Text] [Related]
27. miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.
Samuel P; Pink RC; Brooks SA; Carter DR
Expert Rev Anticancer Ther; 2016; 16(1):57-70. PubMed ID: 26567444
[TBL] [Abstract][Full Text] [Related]
28. [Molecular bases of platinum-resistance in testicular cancer].
Germà-Lluch JR; Piulats JM
Arch Esp Urol; 2013 Jun; 66(5):524-35. PubMed ID: 23793770
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis of cis-diamminedichloroplatinum(II) resistance: a review.
Chao CC
J Formos Med Assoc; 1996 Dec; 95(12):893-900. PubMed ID: 9000804
[TBL] [Abstract][Full Text] [Related]
30. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of cisplatin resistance in bladder cancer.
Drayton RM; Catto JW
Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin: The first metal based anticancer drug.
Ghosh S
Bioorg Chem; 2019 Jul; 88():102925. PubMed ID: 31003078
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms of resistance and toxicity associated with platinating agents.
Rabik CA; Dolan ME
Cancer Treat Rev; 2007 Feb; 33(1):9-23. PubMed ID: 17084534
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin and DNA repair in cancer chemotherapy.
Zamble DB; Lippard SJ
Trends Biochem Sci; 1995 Oct; 20(10):435-9. PubMed ID: 8533159
[TBL] [Abstract][Full Text] [Related]
35. Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy.
Fu R; Zhao B; Chen M; Fu X; Zhang Q; Cui Y; Hu X; Zhou W
Med Oncol; 2023 Dec; 41(1):9. PubMed ID: 38063931
[TBL] [Abstract][Full Text] [Related]
36. Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer.
Yang Y; Li H; Hou S; Hu B; Liu J; Wang J
Oncol Rep; 2013 Aug; 30(2):596-614. PubMed ID: 23733047
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines.
Cetintas VB; Kucukaslan AS; Kosova B; Tetik A; Selvi N; Cok G; Gunduz C; Eroglu Z
Cell Biol Int; 2012 Mar; 36(3):261-5. PubMed ID: 22397496
[TBL] [Abstract][Full Text] [Related]
38. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
39. Translational research offers individually tailored treatments for cancer patients.
Bartelink H; Begg AC; Martin JC; van Dijk M; Moonen L; van 't Veer LJ; Van de Vaart P; Verheij M
Cancer J Sci Am; 2000; 6(1):2-10. PubMed ID: 10696731
[TBL] [Abstract][Full Text] [Related]
40. Ultrasound increases DNA damage attributable to cisplatin in cisplatin-resistant human ovarian cancer cells.
Yu T; Yang Y; Liu S; Yu H
Ultrasound Obstet Gynecol; 2009 Mar; 33(3):355-9. PubMed ID: 19204912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
